HPV-positive head and neck squamous cell carcinoma (HNSCC) is increasingly frequent. Management is particularly debated in the case of postsurgical high-risk features, that is, positive surgical margins and extracapsular spread (ECS). In this increasingly complex emerging framework of HNSCC treatment, representative preclinical models are needed to support future clinical trials and advances in personalized medicine. Here, we present an immunocompetent mouse model based on the implantation of mouse tonsil epithelial HPV16-E6/E7-expressing cancer cells into the submental region of the floor-of-the-mouth. Primary tumors were found to replicate the patterns of human HNSCC local invasion and lymphatic dissemination. To study disease progression after surgery, tumors were removed likely leaving behind residual disease. Surgical resection of tumors was followed by a high rate of local recurrences (>90%) within the first 2-3 weeks. While only 50% of mice had lymph node metastases (LNM) at time of primary tumor excision, all mice with recurrent tumors showed evidence of LNM. To study the consecutive steps of LNM progression and distant metastasis development, LNs from tumor-bearing mice were transplanted into na€ ıve recipient mice. Using this approach, transplanted LNs were found to recapitulate all stages and relevant histological features of regional metastasis progression, including ECS and metastatic spread to the lungs. Altogether, we have developed an immunocompetent HPV-positive HNSCC mouse model of postsurgical local recurrence and regional and distant metastasis progression suitable for preclinical studies.
preclinical models allowing the study of loco-regional recurrence and distant metastasis progression in this particular setting.
Although mechanisms of HPV1 and HPV-negative (HPV2) HNSCC are different, 7 both tumor entities show an invasive phenotype 8, 9 and metastasis into the neck lymph nodes (LNs) and distant sites. [10] [11] [12] Thus, despite their distinct genetic nature 13 and clinico-pathological appearance, 14 treatment approaches of HPV2 and HPV1 HNSCCs are essentially the same and include surgery, radiotherapy, or chemoradiotherapy (cRT) as single or combination modalities, depending on the location and stage of the tumor. Over the past decades, traditional open surgical techniques have been progressively replaced by concurrent cRT from extrapolation of several organ-preservation trials reporting similar oncologic outcomes between both modalities, while minimizing treatment-related morbidity. 15, 16 However, new surgical techniques, such as transoral robotic surgery (TORS) or laser microsurgery (TLM), have gained popularity in the recent years. These techniques have been shown to allow efficient tumor resection while avoiding the morbidity of open approaches. Currently, no evidence supporting nonsurgical over surgical treatments has been reported for advanced stages OPSCC. Up-front concurrent cRT and transoral surgery associated with risk-stratified adjuvant treatments are currently being compared in clinical trials. 17 Surgery allows risk stratification for adjuvant treatment based on the histological examination of the tumor. The potential risk of surgery to leave behind cancer cells is minimized today by intraoperative evaluation of margins and neck dissection. Nevertheless, microscopic residual disease (MRD) resulting from dissemination of cancer cells outside of the evaluated margins 18 carries a high risk of tumor recurrence. Understanding the mechanisms underlying locoregional MRD following surgery might allow the refinement of adjuvant treatments thereby improving outcomes. To this end, immunocompetent mouse models of operable HNSCC, including HPV1 OPSCC, are warranted. Such surrogate models of human diseases are expected to pave the way for new pharmacological and immunotherapeutic modalities.
Here, we present a mouse model that is based on the implantation of the newly established mouse cell line mEERL95 into the neck region of the floor-of-the-mouth (FOM), followed by surgical excision of the invasive primary tumor, monitoring of primary tumor recurrence and transplantation of LNs into recipient mice to study LNM progression and distant metastasis development. The parental mouse mEERL cell line was established by in vitro transformation of male tonsilar epithelial cells with HPV16 E6-E7 proteins and oncogenic H-ras. 19 The mEERL95 cell line was derived from an mEERL tumor grown in a female mouse and extensively characterized in the present work in the context of locoregional MRD after surgery. The techniques presented can be potentially translated into other cellular models of HNSCC, thus allowing for detailed mechanistic studies of postsurgical treatment failures.
Methods

Cell culture
The mEERL95 cell line was derived from a tumor explant of the original mEERL cell line 19 implanted in a C57BL/6JRj female mouse. Both cell lines were grown in Dulbecco's modified Eagle medium/nutrient mixture F-12 (Thermo Fisher Scientific) culture medium supplemented with GlutaMAX, 5% fetal bovine serum (Life Technologies Europe BV), penicillin/streptomycin (Bioconcept) and 13 human keratinocyte growth supplement (HKGS, Thermo Fisher Scientific). Cells were 90% confluent when they were harvested, washed in PBS, counted and resuspended in Hank's Balanced Salt Solution (HBSS, Thermo Fisher Scientific) before injection into mice.
Mice and surgical procedures
All animal experiments were approved by the Ethics Committee for Animal Experimentation of Switzerland and performed within institutional guidelines. Experiments were performed using C57BL/6JRj mice (Janvier Labs, Le GenestSaint-Isle, France) and Prox1-mOrange2 mice on C57BL/6 background. 20 
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tumor-bearing mice was adapted from our previous study 21 and details are provided in Supporting Information, Methods. The recurrent tumors, neck lymph nodes (LNs) and lungs were collected and processed for histopathological and immunostaining studies. The procedure of LN transfer from a tumor-bearing donor mouse into a na€ ıve recipient mouse was adapted from a previously published protocol. 22 Detailed procedure describing orthotopic surgical transfer of LNs is provided in Supporting Information, Methods.
Lymphangiography
For microlymphangiography, anesthetized mice were injected with 5 ml of 8 mg/ml fluorescein-isothyocyanate-dextran (FITC-Dextran; 2000 kDa, Sigma) into the submental area of the neck 15 min before imaging. Mice were then observed under a M205FA stereomicroscope equipped with a DFC300FXR2 camera and AF6000 software (Leica, Wetzlar, Germany).
Quantitative (q) RT-PCR
Total RNA was purified using DirectZol TM RNA MiniPrep Kit (ZymoResearch) and in-column DNase I digestion. 1 mg RNA was converted into cDNA using the High Capacity cDNA RT Kit (Thermo Fisher Scientific). qPCR reactions were performed using 10 ng of freshly diluted cDNA, Fast SyberGreen PCR Master Mix (Thermo Fisher Scientific) and forward and reverse primers at 200 nM. Reactions were analyzed in triplicates on an ABI Prism 7500 fast (Thermo Fisher Scientific). Quantitative relative gene expression was analyzed with DataAssist 3.01 software (Thermo Fisher Scientific) using the comparative CT (DDdCT) values and normalization to mouse Tbp transcript levels. Primer sequences are listed in Supporting Information, Table S1 .
Immunofluorescence and immunohistochemical staining
Five-micrometer frozen sections from mouse and human samples were processed for immunofluorescence staining by a standard protocol that includes fixation with 4% paraformaldehyde in PBS followed by permeabilization with 1% Triton-X100 in PBS. Blocking solution included 0.5% BSA in PBS plus 1% of serum(s) matched with the host species of secondary antibodies. Background reducing agent (Dako, S302283) and mouse FcR-blocker (Myltenyi, 130-092-575) were used to reduce unspecific binding of mouse antibodies. CD31 and PROX1 immunohistochemical staining of paraffin sections from human lymph nodes was performed using a fully automated immunostainer (Ventana Benchmark XT; Ventana Medical Systems, Tucson, AZ) and a multimer detection kit (Ultra-View; Universal DAB; Ventana Medical Systems). Antibodies are listed in Supporting Information, Table S2 . Stained frozen sections were mounted in ProLong V R Gold Antifade Mountant with DAPI (Thermo Fisher Scientific). Fluorescence images were acquired on a Zeiss upright microscope Axio imager Z1 (Zeiss, Oberkochen, Germany). IHC-stained samples were scanned using an Aperio Scanscope XT slide scanner and analyzed with Aperio Imagescope Software (both from Aperio Technologies, Vista, CA).
Histopathological evaluation of mouse samples
The floor-of-the-mouth (FOM) samples including the tongue, the mandible and the attached tumor were surgically extracted from sacrificed mice and divided by a sagittal cut into two pieces, which were processed separately. One tumor-containing fragment including mandible was fixed in 10% neutral buffered Formalin solution (Sigma) and embedded in paraffin, and the second piece after removal of mandible was embedded into Tissue-Tek V R OCT compound (Sakura Finetek). Lymph nodes from the neck were embedded into OCT compound. The lungs were dissected and fixed in 10% neutral buffered formalin solution and embedded in paraffin. Tumor-containing sagittal sections of the FOM, once fixed, were decalcified for 72 hr in chlorohydrate and formic acid solution (both at 4%), embedded in paraffin, sectioned, stained with H&E and examined under the microscope. Paraffin sections of lungs and frozen sections (5 lm) of the OCT-embedded neck lymph nodes were sectioned on three different depths, stained with H&E and examined under the microscope for the presence of metastases. The grading of LNM progression was reported as a simplification of the grading system proposed by Lewis et al. 23 This modified system reported LNM as encapsulated, microscopic ECS, macroscopic ECS and soft-tissue deposit in which no remaining lymphoid tissue is visible under the microscope. The capsular desmoplastic reaction was defined as a significant stromal thickening of the nodal capsule identified on the H&E staining and/or a-SMA staining. Lymphatic space invasion was defined as the presence of at least one Lyve1-positive vessel invaded by cancer cells.
Human samples
Tumor specimen from 42 patients treated in the Department of Otolaryngology-Head and Neck Surgery at the University Hospital of Lausanne (CHUV) between December 1999 and December 2009 were included in the study. Histopathological data were collected and retrospectively reviewed. The Cantonal Department of the Swiss Ethics Committees approved the review of the medical records and the use of the archived tumor specimens for immunostaining studies. Capsular desmoplastic reaction was defined as a significant stromal thickening of the nodal capsule identified on the H&E staining and/or a-SMA staining. Lymphatic space invasion was defined as the presence of at least one CD31/PROX1-positive vessel invaded by cancer cells.
Statistical analysis
Statistical analysis was performed with R software (https:// cran.r-project.org/) and GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA, USA). Only standard statistical tests were performed. For all tests, two-tailed p values of <0.05 were considered statistically significant.
Results
Establishment and features of a new HNSCC mouse tumor model
To test if mEERL cells would establish tumors in the submental region of mice, cells were implanted into male and female mice. While in all male mice, mEERL cells induced fast growing neck tumors (Fig. 1a) , in female mice, tumors irreversibly regressed after 4 weeks except in one mouse, which was sacrificed at Day 45 (Fig. 1a) . The cell line derived by explant culture from this tumor (named mEERL95) had the ability to induce tumors independent of the sex of recipient mice (not shown). Evasion of mEERL95 cells from the female immune system is likely related to the virtually nonexistent expression of the minor histocompatibility Uty antigen encoded by Y-chromosome (Fig. 1b) . This notion is supported by a genotyping PCR, which demonstrated a loss of Y-chromosome in mEERL95 cells (not shown). Most importantly, mEERL95 cells retained expression of MHC class I (H2-D1 and H2-K1; Fig. 1b ) and transporters associated with antigen processing transcripts (Tap1 and Tap2; Fig. 1b) , suggesting intact antigen presentation machinery. These cells continued to express HPV16 E6 and E7 oncogenes (Fig. 1b) . No mutations in E7 transcript were detected by sequencing (not shown).
Tumors established by mEERL95 cells showed an invasive behavior. Cancer cells invaded the lip, mandible and muscles of the FOM (Fig. 1c) . In the lip, nests of cancer cells were found to occupy the lumen of vascular structures (Fig. 1d) . Cancer cells also eroded the mandible (Fig. 1e) , and created satellite metastases in the base of the tongue (Fig. 1f) . Necrotic zones were found in the central areas of tumors (Fig. 1c, asterisk) . Cancer cells were often surrounded by a focally desmoplastic stroma (Fig. 1g) , reflecting the ability of mEERL95 cells to create a fibroblast-rich microenvironment. These stromal cells expressed alpha-smooth muscle actin (a-SMA) (Fig. 2a) , a marker of cancer-associated fibroblasts, which are widely recognized as tumor-promoting cells contributing to the generation of an immunosuppressive microenvironment, therapy resistance and tumor invasion. 24 The invasion front of the tumors showed pushing borders ( Fig. 1c) but also solid strings of cells, detachment of small nests and lobules ( Fig. 2b and 3a) , consistent with a "worst pattern of invasion" (WPOI) type 5 according to the Brandwein-Gensler grading system. 25 Similar to human HPV1 OPSCC, 14 mEERL95 tumors exhibited a nonkeratinizing, poorly differentiated epithelial phenotype with expression of E-cadherin and cytokeratins (Fig. 2b, upper insets) . Many cancer cells co-expressed cytokeratins and/or E-cadherin, along with the mesenchymal protein vimentin (Figs. 2b and 2c), indicating that these cells were undergoing a partial epithelial-mesenchymal transition (EMT). Moreover, some cytokeratin-and vimentin-positive cancer cells embedded into the host stroma lost membranous E-cadherin expression, representing a subpopulation of cells with more advanced EMT (Fig. 2b, dotted inset) . A characteristic feature of mEERL95 tumors is lymphatic space invasion (LSI) determined by the presence of Ecadherin-positive cancer cells inside the capillary lumen of Lyve-1-positive lymphatic vessels in the peritumoral (Fig. 3a) and intratumoral (Fig. 3b) regions. LSI was mostly found in the outer third of the tumor mass (Figs. 3a and 3b ) and in the peritumoral stromal compartment (Fig. 3c) . Systematic analysis of the H&E stained sagittal sections through the primary tumors and surrounding anatomical structures revealed tumor satellites contained in vessel-like structures close to blood vessels and distant from the main tumor mass (>0.2 mm) ( Fig. 3d; also Fig. 1d ), suggestive of satellite metastases. Despite a frequent occurrence of LSI, LN metastases were identified in only 50% of animals usually in subcapsular areas of the head and neck LNs (mandibular, accessory mandibular and cranial deep cervical) (an example is shown in Fig. 3e ), whereas no lung metastases were observed. Collectively, tumors initiated by mEERL95 cells implanted into the submental area of C57BL/6 mice present a highly invasive phenotype with LNMs, offering an attractive model to investigate advanced HNSCC.
Recurrences and LNMs after surgery in mEERL95 model
After tumors were established in the submental area (19.4 6 6.4 days postimplantation; mean tumor volume: 169.5 6 63.7 mm 3 ), 11 mice underwent surgery. We defined two types of surgical resection: complete, when no visible tumor was seen under the dissecting microscope (Fig. 4a) and incomplete, where the mandible and the submental muscular space were colonized by cancer cells limiting resection due to these anatomical barriers (Fig.  4b) . Complete resections could only be accomplished in 3 out of 11 mice (27%). The incidence rate of recurrent tumors was high with 10 out of 11 mice recurring during the first 2 weeks (13 6 5 days). Interestingly, 2 out of 3 animals with complete resections (67%) also developed local recurrences, suggesting that even low-volume MRD leads to recurrences in our model.
To increase the proportion of mice with low-volume MRD, we lowered the surgical threshold. In this cohort, 9 mice underwent microsurgery 14.4 6 2.8 days postimplantation when the mean tumor volume was 95.2 6 26.9 mm 3 . Six out of 9 mice underwent complete macroscopic resection, and 4 out of these 6 mice developed local recurrences a few days later (15 6 5.9 days after treatment) than in the previous cohort.
H&E stained sagittal sections of recurrent tumors revealed a multilocular growth pattern with deposits in the mandible (Fig. 4c1), skin (Fig. 4c2) or base-of-tongue (Fig. 4c3) . The presence of LN metastases was confirmed in all mice with recurrent tumors, and 80% of these mice developed pulmonary metastases (Fig. 4c4) . Thus, we established a model for "residual disease after surgery" that is suitable to study mechanisms of local recurrences and to test treatments targeting residual cancer cells left after surgical resection of tumors. 
Regional LNM progression
To analyze metastases in the regional LNs of the neck, we collected the LNs either during surgical removal of the primary tumor (t1) or when harvesting postsurgical recurrent tumors (t2). At t1, 50% of mice (5 out of 10) presented 1 out of 4 dissected neck LNs with evidence of LNM. These LNM were encapsulated and located in the LN subcapsular region (Fig. 3e) . In contrast, all animals at t2 presented LNMs, including 9 encapsulated LNMs (60%), 5 LNMs with microscopic ECS (33%) and 1 LNM (7%) with macroscopic ECS. No soft-tissue deposit was observed.
To follow further LNM without being limited by the burden of the primary tumor growth, we orthotopically transplanted the LNs from primary-tumor-bearing mice into the neck of na€ ıve recipient mice. The anatomy of the cervical LNs and the transplantation procedure are summarized in Figures 5a and 5b . A successful transplantation of LNM was achieved in 4 out of 7 C57BL/6 recipient mice (57%) and 6 out of 11 recipient Prox1-mOrange2 mice (54%) (Supporting Information, Table S3 ). The latter lymphatic reporter mouse strain was used to test if transplanted LNs are reconnected with the host lymphatic system (see below). In two mice, LNMs successfully developed in 2 out of 4 transplanted LNs, whereas the rest of the mice displayed 1 LNM out of 4 transplanted LNs. The mean elapsed time between LN transplantation and the sacrifice of mice due to a maximum LNM volume of 30 mm 3 was 23.2 6 5.7 days. All LNMs retrieved from transplanted mice at the time of necropsy displayed evidence of ECS at various stages of progression. There was 8 out of 12 LNMs with microscopic ECS (66.6%), 3 out of 12 LNM with macroscopic ECS (25%) and 1 out of 12 with soft tissue deposit (8.3%). Finally, histological evaluation of distant organs of the recipient mice showed evidence of distant metastases. A complete autopsy was performed in a subset of 
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3 animals only. There were 2 out of 3 mice with evidence of multiple pulmonary metastases.
To be considered as a valid orthotopic system, the transplanted LNs should show evidence of reconnection with the host lymphatic system. Therefore, we used the Prox1-mOrange2 transgenic mouse model 20 as recipient animals
and assessed the sprouting and reconnection of their lymphatic system with the transplanted LNs of wild-type C57BL/ 6 mice. Using this approach, transplanted LNs could be discriminated from recipient ones by monitoring the expression of the mOrange2 protein using intravital microscopy. In 5 out of 6 mice with successful LNM transplantation, recipient lymphatic vessels converged in the direction of the donor LNM forming a dense perinodal lymphatic network (Fig. 5c) .
To assess the functionality of the reconnection of the LNs with the host lymphatic network, we performed a microlymphangiography study by injection of FITC-dextran intradermally in the submental area of transplanted Prox1-mOrange2 mice (n 5 5). In 4 out of 5 mice, transplanted LNs were filled by FITC-dextran (Fig. 5d) , a proof of reconnection with the recipient mouse lymphatic system.
Common hallmarks of LNM in mEERL95 model and human samples
To find out if progressing LNMs in mEERL95 model reflect the histological features of human LNM, we performed a comparative study using a set of LNMs obtained from human HNSCC samples (n of LNM 5 42) and mice (n of LNM 5 19: 7 from LN transplantation cohort and 12 from the t2 time point). In this histological investigation, we found that encapsulated, microscopic ECS, macroscopic ECS and soft-tissue deposits typical of human LNM were all represented in the mouse samples (Fig. 6a) . Next, we sought to compare the hallmarks of human LNMs, and we aimed at confirming their presence in mouse samples. Human LNMs showed a stromal desmoplastic reaction around their capsule in 25 out of 26 patients with ECS (96%), whereas it was only present in 9 out of 16 patients (56%) with encapsulated LNMs (p 5 0.00025, Fisher-exact test). We confirmed these findings by immunostaining with the myofibroblastic cell marker a-SMA (Fig. 6b1) . On H&E-stained sections, we additionally observed that LSI was prominent in LNMs with ECS. We confirmed this observation by staining against the pan-vascular marker CD31 (Fig. 6b2 ) and the specific panlymphatic marker PROX1 (Fig. 6b3) . LSI was present in 12 out of 26 patients with ECS (46%), whereas it was found in only 1 out of 16 patients with encapsulated LNM (6%) (p 5 0.0073, Fisher-exact test). Importantly, similar observations were made in mice. Indeed, in all LNMs with ECS (n 5 12: 7 from LN transplantation cohort and 5 from the t2 time point), an intense capsular desmoplastic reaction ( Fig. 6c1 ; as evidenced by a-SMA/E-cadherin co-staining) was found, whereas it was observed only in 1 out of 7 mice without ECS (14%) (p 5 0.0026, Fisher-exact test). LSI ( Fig. 6c2 ; as evidenced by Lyve-1/E-cadherin co-staining) was found in 11 out of 12 mice with ECS (92%), but in only 2 out of 7 mice with encapsulated LNM (40%) (p 5 0.0095, Fisher-exact test). Finally, evaluation of LNM with ECS at the latest stage of progression demonstrated evidence of invasion of adjacent structures such as salivary glands and skin (Fig. 6a, right  panel) , thereby mimicking situations of full-blown ECS at advanced stages in the human setting. Altogether, these results indicate that our mouse model replicates the key cellular features of LNM including ECS observed in human cases.
Discussion
In the present work, we report on the development of a mouse model designed to study postsurgical local recurrence derived from MRD and ECS of LNMs. While the preclinical value of the parental and related cell lines has so far only been explored in the flank mouse model, 26, 27 our approach is the first to successfully integrate implantation of these cells into the submental FOM region with surgery. In this way, we could mimic such clinical cases managed by surgery as a primary treatment. We report that the parental and derivative cell lines can establish invasively growing tumors in an immunocompetent microenvironment. After surgical resection of the primary tumors in the submental area, local recurrences reproducibly develop from MRD and invade into the oral cavity. The mEER family of cell lines, including the mEERL95, have a great potential for the study of MRD and postsurgical recurrences, in particular, to examine the infiltration of cancer cells into the surrounding tissues and their interactions with the immune microenvironment. Tumors established from mEERL95 cells show an infiltrative phenotype and importantly, invade lymphatic vessels within the tumor and into the peritumoral space. This facilitates their local spread far from the tumor front (i.e., satellite metastasis). This finding suggests that LSI may not only contribute to the origin of regional metastasis but also to MRD and local recurrences. Intratumoral lymphatic vessels are expected to be nonfunctional due to high interstitial fluid pressure 28 and, therefore, their role in the transport of cancer cells from the primary tumor to the draining LNs is debatable. In contrast, peritumoral lymphatics 29 could be critical for the occurrence of LN metastasis. Upon application of the suitable strains of transgenic mice as the hosts for mEERL95 cells or agents blocking lymphangiogenesis, a possible contribution of LSI to residual disease and recurrences could be clarified.
The prominent features of mEERL95 tumors consist of partial EMT phenotype and detachment of cancer cell groups at the tumor front. Tumor budding is generally ascribed to the ability of cancer cells to undergo partial EMT, 30 which as opposed to complete EMT is featured by a transient or stable co-expression of epithelial and mesenchymal proteins. 31 Although EMT reliably predicts poor outcome and nodal metastasis in OPSCC independently of their HPV status, 32 the mechanism of EMT may differ between HPV1 and HPV2 OPSCC. 33 Thus, the specific function of cells undergoing EMT in various aspects of tumor biology such as local invasion (that includes LSI and invasion into the soft tissue and bones), metastasis and immunosuppression may also be different. In any event, EMT in HPV1 OPSCC is significantly associated with nodal progression, 34 indirectly supporting the role of EMT in the dissemination of HPV-expressing cancer cells.
The striking feature of our model is a reproducibly frequent metastatic dissemination into the neck LNs and 
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frequent lung metastases in mice after surgery. Thus, the model recapitulates HPV1 OPSCC cases featured by an advanced nodal disease and metastatic dissemination. Also, we provide evidence that orthotopically transplanted LNM recapitulates all the consecutive steps of LNM progression and are functionally reconnected with the host lymphatic system. The technique of LN transplantation has been previously reported in various animal models, including in mice. 22, [35] [36] [37] This approach has mostly been described in the nononcologic settings, specifically in the context of immunerelated questions, LN function and remodeling, and in preclinical models of postsurgical lymphedema. 36 However, only a handful of cancer-related studies used LN transplantation to assess the ability of the transplanted LN to develop a tumor-specific immune response 38 and to trap metastatic cells 39 and to measure metastatic tumor burden in response to chemotherapy 40 and radiation treatment. 41 The orthotopic model that we describe in our work is different as it provides a promising strategy to investigate LNM including routes of distant metastasis and mechanisms of ECS in HNSCC. Our data demonstrate close similarities with all the stages of LNM in human, from encapsulated microscopic LNM to soft tissue deposit and the development of distant metastases. Histological evaluation of transplanted LNM with ECS also demonstrates close similarities with specific hallmarks of this condition, such as an intense desmoplastic reaction in the surrounding stroma and LSI. Although the prognostic significance of ECS is clear in HPV2 HNSCC, its relevance in the context of HPV still needs to be clarified. 42, 43 Nevertheless, our model conveys the potential to disclose the mechanistic and cellular basis of high-risk events within LNMs such as ECS. To the best of our knowledge, only human OSC-19 cell line developed ECS in metastatic LNs after injection into the tongue of SCID mouse. 44 However, ECS has not been reported in an immunocompetent HNSCC model so far. The closest has been the tongue implantation approach using a panel of transplantable and metastatic syngeneic OSCC cell lines derived from C57BL/6 mouse. 45 However, ECS in LNM have not yet been addressed in this very promising model.
We are aware of some limitations of the cell lines used in this study which need to be taken into consideration for the design and interpretation of future mechanistic studies. Given that HPV1 HNSCCs infrequently (4%) harbor mutations in HRAS gene, 13 the model could be considered to be somewhat artificial, not reflecting typical molecular events of HPV1 disease. However, mechanisms of malignant transformation of oral epithelial cells in human and mouse, as it is known for fibroblasts, 46 are very likely similar but not necessarily identical. Hence, there is a need for further research on the species-specific requirements of head and neck epithelial tumorigenesis. Nevertheless, the panel of mEER cell lines is suitable for preclinical testing of immunotherapeutic agents like E7-specific vaccines, immune-modulating antibodies, and novel targeted or combination adjuvant therapies. Importantly, gender-independent tumor growth in immunocompetent C57BL/6 mice provides an advantage to design studies with male and female tumor-bearing mice avoiding a genderspecific bias in the therapy response. Last, head and neck cancer cell lines derived from C57BL/6 genetic background, such as the MOC panel 45 and mEER cell lines together with its derivates, present an advantage in comparison to the Balb/C (B4B8-Scid, 47 PAM 212 48 and PAM-LY (LY-2) 49 ) and C3H (AT-84 50 ) strain derived cell lines, due to the diversity of transgenic C57BL/6 strain-based models.
In conclusion, we believe that our preclinical immunocompetent mouse model of HPV1 HNSCC holds the promise to experimentally address the most critical problems related with treatment failures.
